JP2010248271A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010248271A5 JP2010248271A5 JP2010177655A JP2010177655A JP2010248271A5 JP 2010248271 A5 JP2010248271 A5 JP 2010248271A5 JP 2010177655 A JP2010177655 A JP 2010177655A JP 2010177655 A JP2010177655 A JP 2010177655A JP 2010248271 A5 JP2010248271 A5 JP 2010248271A5
- Authority
- JP
- Japan
- Prior art keywords
- microparticle
- weight
- phospholipid
- amount
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000011859 microparticle Substances 0.000 claims 15
- 150000003904 phospholipids Chemical class 0.000 claims 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 229920002988 biodegradable polymer Polymers 0.000 claims 4
- 239000004621 biodegradable polymer Substances 0.000 claims 4
- 239000010419 fine particle Substances 0.000 claims 4
- 229940067606 lecithin Drugs 0.000 claims 4
- 235000010445 lecithin Nutrition 0.000 claims 4
- 239000000787 lecithin Substances 0.000 claims 4
- 229920003169 water-soluble polymer Polymers 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- 241001149724 Cololabis adocetus Species 0.000 claims 1
- 229920001634 Copolyester Polymers 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 229920001710 Polyorthoester Polymers 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- -1 alkylene diol Chemical class 0.000 claims 1
- 125000005263 alkylenediamine group Chemical group 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920002627 poly(phosphazenes) Polymers 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10211040 | 2002-03-13 | ||
| DE10213856 | 2002-03-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574167A Division JP4679822B2 (ja) | 2002-03-13 | 2003-03-12 | 医薬微粒子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014000306A Division JP2014058580A (ja) | 2002-03-13 | 2014-01-06 | 医薬微粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010248271A JP2010248271A (ja) | 2010-11-04 |
| JP2010248271A5 true JP2010248271A5 (cg-RX-API-DMAC7.html) | 2011-09-29 |
Family
ID=27806083
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574167A Expired - Fee Related JP4679822B2 (ja) | 2002-03-13 | 2003-03-12 | 医薬微粒子 |
| JP2010177655A Ceased JP2010248271A (ja) | 2002-03-13 | 2010-08-06 | 医薬微粒子 |
| JP2014000306A Pending JP2014058580A (ja) | 2002-03-13 | 2014-01-06 | 医薬微粒子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574167A Expired - Fee Related JP4679822B2 (ja) | 2002-03-13 | 2003-03-12 | 医薬微粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014000306A Pending JP2014058580A (ja) | 2002-03-13 | 2014-01-06 | 医薬微粒子 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20050152980A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1485070A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP4679822B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003221497A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003075892A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003075892A1 (en) * | 2002-03-13 | 2003-09-18 | Novartis Ag | Pharmaceutical microparticles |
| MY158342A (en) | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
| JP2008530206A (ja) * | 2005-02-17 | 2008-08-07 | メディバス エルエルシー | ポリマー粒子送達組成物および使用法 |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| KR100682334B1 (ko) * | 2006-07-14 | 2007-02-16 | (주)지에프씨 | 미립상 레시틴 왁스 조성물 제조장치 |
| CN100540585C (zh) * | 2006-08-02 | 2009-09-16 | 四川大学 | 含磷脂酰胆碱基团的可生物降解聚酯及其制备方法 |
| AU2008310956B2 (en) * | 2007-10-08 | 2014-08-07 | Aurinia Pharmaceuticals Inc. | Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors |
| US20110223216A1 (en) * | 2008-11-17 | 2011-09-15 | Wayne State University | Nanoparticles and Porous Particles and Methods of Making the Same |
| AU2010259184B2 (en) | 2009-06-09 | 2015-08-13 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| US9211377B2 (en) | 2009-07-30 | 2015-12-15 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| DE112015005320T5 (de) * | 2014-11-25 | 2017-08-31 | Cbc Co., Ltd. | Janus Nanopartikel und Verfahren zur Herstellung derselben |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| US10953103B2 (en) | 2015-11-06 | 2021-03-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V | Composition comprising a biocompatible and biodegradable polymer, nanocarriers and a drug and methods of making and using the same |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| EP4036079B1 (en) | 2015-12-22 | 2025-11-19 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
| LT3394093T (lt) | 2015-12-23 | 2022-04-25 | Modernatx, Inc. | Ox40 ligandus koduojančių polinukleotidų naudojimo būdai |
| WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| MX391377B (es) * | 2016-05-13 | 2025-03-21 | Merck Patent Gmbh | Tamaño de particula y distribucion de polimero para aplicacion de extrusion de fusion. |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| JP2018095616A (ja) * | 2016-12-15 | 2018-06-21 | 国立大学法人 宮崎大学 | アドレノメデュリン徐放性製剤 |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| AU2018234814B2 (en) | 2017-03-15 | 2022-06-30 | Modernatx, Inc. | Crystal forms of amino lipids |
| RS63953B1 (sr) | 2017-03-15 | 2023-02-28 | Modernatx Inc | Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| AU2019258844B2 (en) | 2018-04-27 | 2025-01-30 | Fresh Inset S.A. | Compositions and articles comprising complexes of 1-methylcycloproprene and alpha-cyclodextrin |
| EP3852732A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Peg lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CA3141857A1 (en) * | 2019-04-23 | 2020-10-29 | Amgen Inc. | The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations |
| US20230210763A1 (en) * | 2019-09-19 | 2023-07-06 | Amw Gmbh | Extruded depot form for controlled active substance release |
| AR120080A1 (es) | 2019-09-19 | 2022-02-02 | Modernatx Inc | Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos |
| PE20230411A1 (es) | 2020-02-03 | 2023-03-07 | Fresh Inset S A | Composiciones estables de 1-metilciclopropeno y usos de las mismas |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5432436B2 (cg-RX-API-DMAC7.html) * | 1972-05-13 | 1979-10-15 | ||
| US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
| DE3917617A1 (de) * | 1989-05-31 | 1990-12-06 | Boehringer Ingelheim Kg | Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung |
| FR2651680B1 (fr) * | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | Nouveau procede de preparation de microparticules lipidiques. |
| DE3934656A1 (de) | 1989-10-13 | 1991-04-18 | Schering Ag | Verfahren zur herstellung von waessrigen dispersionen |
| ATE102022T1 (de) * | 1990-08-30 | 1994-03-15 | Senju Pharma Co | Zusammensetzung zur kontrollierten abgabe von medikamenten. |
| IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US6090925A (en) * | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| EP1649850A1 (en) * | 1993-11-19 | 2006-04-26 | Alkermes Controlled Therapeutics Inc. II | Preparation of biodegradable microparticles containing a biologically active agent |
| GB9412273D0 (en) | 1994-06-18 | 1994-08-10 | Univ Nottingham | Administration means |
| AU4755696A (en) * | 1995-01-05 | 1996-07-24 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Surface-modified nanoparticles and method of making and using same |
| US5718922A (en) * | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
| DE19545257A1 (de) * | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| AU733867B2 (en) * | 1996-06-24 | 2001-05-31 | Euro-Celtique S.A. | Methods for providing safe local anesthesia |
| US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
| WO2000003660A1 (en) * | 1998-07-17 | 2000-01-27 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| GB9906695D0 (en) * | 1999-03-24 | 1999-05-19 | Secr Defence | Vaccine composition |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| ATE462413T1 (de) * | 2000-01-14 | 2010-04-15 | Univ Brown Res Found | Verfahren zur herstellung von mikronisierte gefriergetrocknete partikeln |
| US20030064105A1 (en) * | 2000-08-25 | 2003-04-03 | Myung-Jin Kim | Lipophilic-coated microparticle containing a protein drug and formulation comprising same |
| WO2001055360A1 (en) * | 2000-01-28 | 2001-08-02 | Infimed Therapeutics, Inc. | Slow release protein polymers |
| AU2001252588A1 (en) * | 2000-04-28 | 2001-11-12 | Tanabe Seiyaku Co., Ltd. | Method for preparing microsphere |
| WO2003075892A1 (en) * | 2002-03-13 | 2003-09-18 | Novartis Ag | Pharmaceutical microparticles |
| AU2003288902A1 (en) * | 2002-09-06 | 2004-04-08 | Genteric, Inc. | Microcapsules and methods of use |
| US20080286375A1 (en) * | 2005-11-15 | 2008-11-20 | Amorepacific Corporation | Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate |
-
2003
- 2003-03-12 WO PCT/EP2003/002565 patent/WO2003075892A1/en not_active Ceased
- 2003-03-12 EP EP03717207A patent/EP1485070A1/en not_active Withdrawn
- 2003-03-12 AU AU2003221497A patent/AU2003221497A1/en not_active Abandoned
- 2003-03-12 US US10/506,822 patent/US20050152980A1/en not_active Abandoned
- 2003-03-12 JP JP2003574167A patent/JP4679822B2/ja not_active Expired - Fee Related
-
2008
- 2008-07-17 US US12/218,639 patent/US8110224B2/en not_active Expired - Fee Related
-
2010
- 2010-08-06 JP JP2010177655A patent/JP2010248271A/ja not_active Ceased
-
2012
- 2012-01-11 US US13/348,114 patent/US8460709B2/en not_active Expired - Fee Related
-
2013
- 2013-04-26 US US13/871,064 patent/US20130236550A1/en not_active Abandoned
-
2014
- 2014-01-06 JP JP2014000306A patent/JP2014058580A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010248271A5 (cg-RX-API-DMAC7.html) | ||
| JP5841708B2 (ja) | 表面被覆微粒子の医薬組成物 | |
| US6706289B2 (en) | Methods and compositions for enhanced delivery of bioactive molecules | |
| Fu et al. | New polymeric carriers for controlled drug delivery following inhalation or injection | |
| Blanco-Prı́eto et al. | Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres | |
| JP5491119B2 (ja) | 薬物含有微粒子を含む医薬組成物およびその製造方法 | |
| K Garg et al. | Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers | |
| Thomas et al. | Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses | |
| Lavelle et al. | The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol | |
| WO2003041689A1 (en) | Biocompatible polymer blends and uses thereof | |
| CA2405030A1 (en) | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix | |
| CA2565296C (en) | Sustained-release microspheres and methods of making and using same | |
| JP2009512682A5 (cg-RX-API-DMAC7.html) | ||
| JP2010235584A5 (cg-RX-API-DMAC7.html) | ||
| WO1997013502A2 (en) | Prolonged release of gm-csf | |
| CN1856295A (zh) | 控释组合物 | |
| JP2020513420A (ja) | 負の表面電荷を有するマイクロ粒子及びナノ粒子 | |
| TWI630929B (zh) | 微膠囊製劑及其製造方法 | |
| Zhang et al. | Absorption-improving effects of chitosan oligomers based on their mucoadhesive properties: a comparative study on the oral and pulmonary delivery of calcitonin | |
| Pandit et al. | Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against hepatitis B through incorporation of alum and chitosan | |
| JP2019534897A5 (cg-RX-API-DMAC7.html) | ||
| Davies et al. | Surface modification of microspheres with steric stabilizing and cationic polymers for gene delivery | |
| Yoon et al. | In vivo residence duration of human growth hormone loaded in nanogels comprising cinnamoyl alginate, cinnamoyl Pluronic F127 and cinnamoyl poly (ethylene glycol) | |
| Zhang et al. | Recombinant interferon-alpha2b poly (lactic-co-glycolic acid) microspheres: pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration | |
| JP2021523137A (ja) | 生体吸収性ポリエステル、親水性ポリマーおよびアシル化ヒトラクトフェリン由来ペプチドを含むナノ粒子 |